Upload
jeremy-bell
View
222
Download
0
Embed Size (px)
Citation preview
7/28/2019 Biomaterial Research Japan
1/69
1
EMBASSY OF FINLANDNational Technology Agency3-5-39, Minami-Azabu
Minato-ku, TOKYO 106-8561Tel:+81 3 5447 6035 Fax:+81 3 5447 6046
TEKES/TOKYO TECHNOLOGY SCANNING
Biomaterial Research in Japan
February 22, 2001
Tadaaki (Todd) Toyoshima
TEKES, Tokyo
Preface
This report lists who does what in the various fields of biomaterial research in Japan. Literature surveys
and interviews with researchers are recommended in order to more thoroughly research a specific
theme or topic. Tekes Tokyo will be pleased to help you in this respect.
Additional information: [email protected]
7/28/2019 Biomaterial Research Japan
2/69
2
Content
1 Strength and Weakness of Biomaterials in Japan.............................................................................................................42 Market ..................................................... ........................................................... .......................................................... ....4
3 Research on Biomaterials.................................................................................................................................................93-1 Academic Societies.................................................................................................................................................9
3-2 Major Biomaterial Research Groups ....................................................... ................................................................. ....10
4 Ceramics.........................................................................................................................................................................11
4-1 Introduction ..........................................................................................................................................................11
4-2 Artificial Bone Market..........................................................................................................................................12
4-3 Calcium Phosphate Paste......................................................................................................................................14
4-4 Advanced bone materials......................................................................................................................................14
4-5 Bone generation---tissue engineering ...................................................................................................................16
4-6 Drug delivery system using ceramics ...................................................................................................................18
4-7 Ceramics for cancer treatment ..............................................................................................................................18
5 Metal ..............................................................................................................................................................................18
5-1 Artificial Joints Market.........................................................................................................................................18
5-2 Titanium alloy on the market................................................................................................................................20
5-3 Titanium alloy under research ..............................................................................................................................21
5-4 Metals for dental application ................................................................................................................................21
5-5 Surface modifications ...........................................................................................................................................22
5-6 Other Metals .........................................................................................................................................................23
6 Polymers and Lipids.......................................................................................................................................................23
6-1 MS Coat................................................................................................................................................................24
6-2 MPC......................................................................................................................................................................24
6-3 Photoreactive polymers ........................................................................................................................................24
6-4 PIPAAm................................................................................................................................................................25
6-5 Polymeric Micelles ...............................................................................................................................................26
6-6 Nanoparticles and Microcapsules .........................................................................................................................26
6-7 Liposomes.............................................................................................................................................................27
6-8 Polysilamine .........................................................................................................................................................27
6-9 Perflourocarbonic acid..........................................................................................................................................28
6-10 Shape Memory Gels .............................................................................................................................................286-11 Hollow fibres ........................................................................................................................................................28
7 Drug Delivery and Targeting .........................................................................................................................................29
7-1 Overall situation ...................................................................................................................................................30
7-2 Active targeting ....................................................................................................................................................32
7-3 Passive Targeting..................................................................................................................................................32
7-4 Stimulus Responsive Materials.............................................................................................................................327-5 Electromagnetic Responsive Double Targeting....................................................................................................33
7-6 Biomolecular Design for Biotargeting..................................................................................................................337-7 Transdermal & Transmucosal Delivery................................................................................................................34
7-8 Company activities ...............................................................................................................................................35
8 Gene Delivery ................................................................................................................................................................36
8-1 Gene Therapy Protocols .......................................................................................................................................368-2 Research on non-virus vectors..............................................................................................................................37
8-3 Polycations and Liposomes ..................................................................................................................................37
8-4 Polymer Micelles ..................................................................................................................................................38
8-5 Fullerene and Cyclodextrin...................................................................................................................................38
9 Tissue Engineering.........................................................................................................................................................399-1 Regenerative Medical Engineering Programme by the Ministry of Education ....................................................39
9-2 The Yoshizato Group at Hiroshima University ....................................................................................................42
9-3 3D Tissue Module Engineering conducted by NAIR...........................................................................................43
9-4 Millennium Project...............................................................................................................................................43
7/28/2019 Biomaterial Research Japan
3/69
7/28/2019 Biomaterial Research Japan
4/69
4
1 Strength and Weakness of Biomaterials in Japan
Japan is a world leader in dialysis membranes and artificial kidneys, with more than 50% of the world
market, owing in part to large fibre manufacturers such as Toray and Asahi Chemical. Furthermore,
Japanese companies excel at disposable materials. In contrast, most implant materials are imported,
with one exception, ceramic bone. Japan has been historically strong in ceramics, not to mention
electronic condensers and fine ceramics in the semiconductor industry. Developments in metal for
artificial joints are also catching up with the West.
There are many biomaterial researchers in Japan. But, Japanese companies are reluctant to take the risk
to be a pioneer in implant applications or prostheses. Japan's strength lies in external rather than
implanted components and devices. Most implanted materials have been developed in the West.
Components used in interface areas, such as dental materials and contact lenses, are both made in Japanand imported.
In Japan, researchers, in close collaboration with clinical doctors, have the advantage in discovering
clinical needs and conducting clinical trials. In this respect, bio-material institutes in medical
universities have many actual products to bring to market.
Most material researchers consider the future of biomaterials to be in tissue engineering or, more
narrowly, human cell engineering.
With regard to drug delivery systems (DDS), Japan has put successful DDS products on the market,
such asLeuprin, polymer nanosphere DDS; and SMANCS, a drug-polymer conjugate suspended in
lipiodole. Adhesive transdermal delivery systems, such as pressure sensitive adhesives containing
isosorbide dinitrate, are also advanced. Many controlled release type DDS have been developed and the
future seems to be in organ, cell, and molecule targeting.
In tissue engineering, there are at least three government-supported programmes under way.
The government has selected tissue engineering as one of the Millennium Projects, starting two
research institutes in the Kobe area: one for basic study and another for application.
2 Market
Japan imports most of its implant materials or devices. Valves for artificial hearts are 100% imported;
artificial blood vessels, 95%; bone bonding materials, 80%; artificial joints, more than 80%; and pace-
makers, 90%.
7/28/2019 Biomaterial Research Japan
5/69
Medical equipment and materials market in Japan
Production
(million
Yen)
Import
(million
Yen)
Expor
(millio
Yen)
Grand Total 1,487,903 834,509 365,042
Image diagnostics
systems
298,356 82,872 127,215
Treatment
equipment
194,395 196,049 46,408
Measuring and
monitoring systems
172,116 46,393 95,011
Total 163,445 267,879 28,232
Heart Valves 7 11,551
Pacemakers 55 44,042
Blood Tubes 109 5,941
Stents 384 14,905 16
Joints and Bones
total
20,187 84,534 10
Hip joints 8,195 20,167 10
Knee joints 1,234 13,969
Shoulder joints 139 358
Elbow joints 97 917
Metal bone 63 2,995
Resin bone 250 274
Ceramic bone 2,937 19Bone bonding
materials
5,442 41,061
Bone cement 44 1,789
Devices and
Equipment for
Function Support or
Replacement
Joints and Bones
Other related 1,781 2,979
7/28/2019 Biomaterial Research Japan
6/69
Intraocular Lens 3,936 12,268
Monitors & liquid
supply for dialysis
13,842 421 1,213
Dialysis equipment 73,912 2,499 22,094
Pumps &accessories for
Artificial Lungs
1,429 3,582 372
Artificial Lungs 2,261 2,922 678
Blood Cleaning
equipment
14,834 4,906 1,856
Blood circuits 11,962 15,101 1,072
Home Use Medical
equipment
151,691 8,048
X ray equipment 103,074 43,511 16,618
Total 90,752 17,026 2,142
Metal 50,378 4,005 27
Crowns (4/5 are resin) 6,022 907 232
Dentures (Almost all are
resin)
2,825 165 211
Bonding, Filling
materials
(1/2 are resin) 14,970 3,653 1,600
Impression
materials
5,278 1,180 17
Dental materials*
Others 5,071 547 33
Eye-related
equipment
87,647 49,129
Biopsy inspection
equipment
85,066 22,329 19,796
Healing & surgery
equipment
61,843 50,755 7,126
7/28/2019 Biomaterial Research Japan
7/69
Dental equipment 35,767 7,616
Equipment for
facility
29,095 2,979
Steel equipment 8,080 21,966
Hygiene materials 6,575Source: Ministry of Health and Welfare Medical Industry Statistics 1999.
*Issued a report, in Japanese, on The Market for Dental Equipment, Materialsand Chemicals published
Research Institute, is available (cost - Yen 100,000).
Medical equipment and materials market in JapanGrand total growth rate
Production Import Export
1995 1.4 % 17.5 %
1996 8.9 20.5 11.3 %
1997 4.0 5.8 21.8
1998 -0.4 11.2 21.7
1999 -1.3 0.0 35.8
The shipment and growth rates of implant materials
Shipment in 1999
(100 million Yen)
Growth rate in
1998/1997
(%)
Growth rate
Forecast in
1999/1998(%)
Cardiovascular equipment and
materials
710 7.4 15
Artificial bones and joints 513 -17.8 10
7/28/2019 Biomaterial Research Japan
8/69
Blood cleaning and separation
equipment
372 43 No data
Dialysis equipment 748 10 10
Total 2,524 7.7
Source:Market for Medical Equipment and Materials, Yano Research Institute.
7/28/2019 Biomaterial Research Japan
9/69
9
3 Research on Biomaterials
3-1 Academic Societies
According to Dr. Tsuruta, Emeritus Professor, Tokyo University, Japan has a long history in
biomaterials. Research on polymers for medical use started in 1958. The Higuchi model for a drug
delivery system was reported in 1961. The Toray PMMA hollow fibres for artificial dialysis were put
on the market in 1973 and the Kuraray EVA in 1978. The Ministry of Education funded biomedical
polymer research programmes from 1972 through 1989 under various programme names.
Prof. Tsuruta emphasised, in his keynote speech at the 2000 Biomaterial Conference, that all the
development work should have clinical applications as the target. He encouraged researchers to protectthemselves against unreasonable lawsuits. Companies should develop their risk management strategies
to deal with the biomaterial products and business. He predicted that future biomaterial research would
shift to tissue engineering.
The following academic societies are focused or have groups focused on biomaterials:
Japanese Society for Biomaterials was founded in 1978. It organises an annual conference and
publishes a bimonthly journal in Japanese. In addition to individual members, there are about 50
company members. The next annual conference will be held in Kyoto on October 22 and 23, 2001.
The Ceramics Societyof Japan formed a Bio-related Materials Working Group in October 1998. Thegroup has about 120 members and holds a conference and a Beginners Seminar once a year in
November or December. The society publishes two Japanese monthly publications calledJournal of
Ceramic Society of Japan (for papers) and Ceramics Japan (for reviews).
Japan Metal Society has a temporary (March 1998February 2001) group called High Performance
Biomaterial Study Committee. The committees aim is to review the appropriate data for the
development of biomaterials, and to decide the current status of evaluation methods and standards.
There are no industrial standards for biomaterials in Japan.
The Society of Polymer Science, Japan has a Research Group on Biomedical Polymers, which was
founded in 1972. The research group, 150 members, holds conferences on special themes, and review-type seminars. The society publishes an English-language monthly calledPolymer Journal.
Japan Society of Medical Electronics and Biological Engineering was founded in 1962, and now
has 4,000 members. It publishes an English-language quarterly calledFrontiers of Medical and
Biological Engineeringas well as a monthly journal in Japanese.
Japan Society of Drug Delivery Systems was founded in 1988 based on the DDS Study Group that
began in 1984. It now organises annual conferencesthe next is on July 12, 2001 in Osaka with
around 500 researchers expected to attend. The Society publishes a bi-monthly journal in Japanese
calledDrug Delivery System. The number of members is over 1,000. The Japanese Society of Drug
7/28/2019 Biomaterial Research Japan
10/69
10
Delivery Systems jointly publishes theJournal of Controlled Release (JCR) with the international
Controlled Release Society.
Japan Society for Tissue Engineeringbegan in 1984 asthe Organ Formation Working Groupandadopted its current name in 1998. It organises an annual meeting but does not publish a journal. Rather
it encourages Japanese members to send papers to Tissue Engineeringin the USA.
3-2 Major Biomaterial Research Groups
Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental UniversityThe oldest biomaterials research institute in Japan has three divisions: the Functional Molecule
division; the Materials divisionmetal, inorganic and organic materials; and the Bio Systems division.
The institute started dental material research in 1938 and diversified in 1966 to cover other medical
fields. It has more than 50 permanent researchers.
Tissue Engineering Research Institute at the Institute of Frontier Medical Sciences, Kyoto
UniversityThis institute is one of the largest Japanese research groups in tissue engineering. The institute was
founded in 1978 as the Medical Polymer Research Group and developed into the Research Center for
Medical Polymers in 1980, changing its name to Research Center for Biomedical Engineering in 1990,
and adopting the current name in 1998. With approximately 80 researchers, it covers all fields relatedto tissue engineering: biological function, tissue engineering, regeneration control, medical system
engineering, and clinical applications.
Professor Ikada was former head research director of the institute.
Institute of Biomedical Engineering, Tokyo Womens Medical UniversityProf. Okano, head of the institute, is an expert in temperature responsive polymers and his group is
working on applications of the polymers for DDS and gene vectors. Cell Sheet Engineering
technology is one of the approaches, promoted by the Institute, to produce complicated organs by
accumulating cell sheets one by one using temperature responsive surfaces, similar to the building of
large-scale integrated circuits. They recently started collaboration with the Science & Engineering
Department of Waseda University.
Professor Yoshizato's group, at Hiroshima University. This group is unique in that they are targeting
technology development based on tissue engineering to promote local industry, getting support from
both the central and local government and from close collaboration with companies.
3D Tissue Module Engineering group in NAIR
The 3D Tissue Module Engineering groupin the National Institute for Advanced Interdisciplinary
Research, under the Ministry of Economy and Industry, was formed in 1998 with more than 40
7/28/2019 Biomaterial Research Japan
11/69
11
researchers, including 11 foreign researchers. This group will likely be a core member in the new
laboratory in Osaka called METI Tissue Engineering Center, to be founded in 2002.
The International Symposium on Advanced Biomaterials and Tissue Engineering held in 1999 wasorganised by NAIR to promote industrial applications.
National Research Institute for Metal and National Institute for Research in Inorganic Materials,
bothunder the Ministry of Education and Science, are merging in April 2001. Each institute has a
biomaterial research group. After the merger, they will have approximately 15-20 researchers.
4 Ceramics
4-1 Introduction1
According to Prof. Nakamura, Kyoto University, there have been three generations of artificial bone:
the first generation is sintered hydroxyapatite (HAP) and A-W glass ceramics, the second generation is
porous material and Ca-P cement, and the third is the material together with a complex of bone growth
factors and bone cells.
Three materials for bone replacement have been invented since the 1970s: Bioglass, Sinteredhydroxyapatite, and Crystallised glass A-W. Japanese researchers have made a large contribution to thelatter two.
Dr. H. Aoki, former professor at the Tokyo Medical and Dental University, succeeded in synthesising
HAP and manufacturing sintered HAP in 1972, simultaneously but independently from investigators in
the USA. He discovered the high affinity of HAP to real bone in 1975. His research theme for
developing the manufacturing technology of synthesised HAP for artificial bone and teeth was funded
by the Ministry of Education for five years beginning in 1977.Apaceram now sold by Asahi Pentax
Co., the top market shareholder of bioceramics in Japan, is based on his research.
Prof. Kokubo, from Material Chemistry at the Kyoto University, announced in 1982, and began usingin 1991, Crystallised Glass A-W (SiO2-CaO-MgO-P2O5), which is made by the deposit of fine crystals
of HAP and wollastonite: CaOSiO2. Nippon Electric Glass Co. has sold A-W as Cerabone since 1991,
with annual sales of approximately USD 7 million. It has been used on 45,000 patients. They decided,
however, in October 2000 to discontinue the business at the end of 2000, because of slow growth and
the poor prospect for future profits.
7/28/2019 Biomaterial Research Japan
12/69
12
Comparison of physical properties
Bioglass HAP A-W Dense
natural bone
Spongy
natural bone
Density gcm-3
2.68 3.16 3.07 1.6-2.1Hardness HV 458 600 680
Compressed strength
MPa
500-1000 1080 100-230 2-12
Bending strength
MPa
42 115-200 215 50-150
Young modulus
GPa
35 80-110 118 7-30 0.05-0.5
Breaking tenacity
MPam1/2
1.0 2.0 2-6
Bone invasion speed
into ceramics space
Highest Low high
Containing SiO42-
(may be toxic)
Yes No Yes
Source: L.L.Hench (1998)J.Am. Ceram. Soc., 81, 1705-28
Increasing the tenacity and decreasing the Young Modulus of artificial bone to the level of natural bone
is a major challenge. One method of increasing tenacity is to coat titanium alloy with HAP. Another
approach is to use collagen-apatite composites. Hybrid materials of organic and inorganic components,
bonded at the molecular level to produce material similar to spongy bone, are being investigated.
Ceramics that can be moulded in surgery rooms are also required. Mitsubishi Material Co. has
developed biodegradable calcium phosphate bioactive paste (major component: a-Tri-Calcium
Phosphate) independently from Norian. Mitsubishi started selling the product called BIOPEX in June
2000 through the Welfide Corporation and Taisho Pharmaceutical Co.
Ceramics are also used in cancer treatment and drug delivery systems.
The major direction of current research is to develop materials to promote bone generation by means of
tissue engineering.
4-2 Artificial Bone Market
Market2
In 1998, the market size was USD 35 million, with a 4-5% growth rate expected until the market for
osteoporosis treatment takes off. The markets for artificial bones in foreign countries are small because
human and animal bones can be easily used. In Japan, such reuse is disliked for social and religious
reasons.
7/28/2019 Biomaterial Research Japan
13/69
13
There are two types of artificial bones: ceramics and resin. Sales of artificial bone ceramics totalled
USD 30 million and are growing. Artificial bone resin sales were USD 2 million in 1997 and have
levelled off. A liquid type resin, which solidifies within the human body, has attracted attention due topotential use in osteoporosis treatment, such asBIOPEXby the Mitsubishi Material Co.
Manufacturers
Manufacturers sales figures
Makers Sales
representative
Sales in
1999
(million
Yen)
Brand names and product types
Asahi Optical Asahi Optical 1,410 APACERAM: HAPNippon Special
Ceramics
Chugai
Pharmaceutical
600 CERATITE: Complex of HAP and
tri-calcium phosphate (TCP)
Sumitomo Osaka
Cement
Sumitomo
Pharmaceutical
560 BONECERAM: HAP
Both porous and dense types are
available.
Nippon Electric
Glass
Discontinued
bioglass business
Dec. 2000
415 BIOGLASS A-W
Mitsubishi
Materials
Welfide
Corporation
331 BONEFILL and BONETIGHT: HAP
BIOPEX: Paste ofa-TCP and 4CP
Kyocera Welfide 240 BIOCERAM: TCP
(Kyocera is an artificial joints
manufacturer)
Olympus Olympus 100 Osferion: b-TCP
Both porous particles and blocks are
available.
Source: The Market for Dental Equipment, Materialsand Chemicals, October 1999, Yano Research.
Direction of technology
Hard bone:
Increase of bone-forming ability with marrow transplanting and bioactive substances
Mitsubishi calcium phosphate paste will be followed by competitors
Composites
Soft bone or cartilage:
Replacement of cartilage with artificial bone has not yet succeeded clinically; therefore, joints need
to be completely replaced.
7/28/2019 Biomaterial Research Japan
14/69
14
The abrasion of joint sliding surfaces is still a challenge to be solved. Alumina-alumina sliding
surfaces and the composites of zirconia and alumina are under study.
4-3 Calcium Phosphate Paste
BIOPEX
Mitsubishi Materials Co. launched a calcium phosphate paste in June 2000. The National Health
Insurance system listed the material in 1999.
At the Japan Biomaterial Conference held in November 2000, Dr Shigeo Miwa from the Aichi Medical
University, reported the clinical trial results of Mitsubishi MaterialBIOPEX.
BIOPEX components arePowder:
Ca3(PO4)2: 75 % of the weight
Ca4(PO4)2O: 18
CaHPO42H2O: 5
Ca10H(PO4)6(OH)2 2
Liquid:
5 % chondroitin sulphate
12 % sodium succinate
83 % distilled water
BIOPEXcompletely changes to apatite in the body in three weeks. Its degree of crystallisation is low
and is similar to human bone. Unlike PMMA cement, it does not generate polymerisation heat nor
leach non-polymerised monomers to the cardiovascular system. The material is gradually absorbed by
the body: 50 % in 3 weeks. Its shortcoming is the weak compressive strength: 6090 M Pa. Therefore,
it is not suitable for artificial bone fixing.3
At the Biomaterial Symposium 2000, S. Yamamoto, of the Department of Oral Functional Science, at
the Hokkaido University, in co-operation with Asahi Optical Co., presented an application of Calcium
Phosphate Cement containing CM-chitin and succinic acid for bone augmentation. In rabbits, he
observed new bone formation in a crack in the skull.
4-4 Advanced bone materials4
Many researchers are still trying to develop next generation apatite using composites and surface
modification.
Nitta Gelatin Inc., together with Dr. Junzo Tanaka and Dr. Masanori Kikuchi, of the National Institute
for Research in Inorganic Materials, has developed artificial bone that has a flexural strength of about
7/28/2019 Biomaterial Research Japan
15/69
15
50 MPa, nearly comparable to that of the human bone (40200 MPa). It is a composite consisting of
protein-I type collagen and hydroxyapatite. A co-precipitate of a calcium hydroxide solution and an
aqueous phosphate solution containing collagen is formed via a cold isostatic pressure process. When
the new composite was transplanted onto a rat cranial bone, the composite started to be replaced bynatural bone in two weeks.
Nitta Gelatin Inc. is also manufacturing collagen for artificial skin in medical treatment.
National Industrial Research Institute of Nagoya has found that chitin and chitosan derivatives
containing phosphoric acid are effective in forming bone. The surface of chitin or chitosan is
modified by phosphoesterification and the derivative put into phosphoric acid and calcium-containing
liquid. After 10 days, the same volume of calcium phosphate as the derivative was obtained.
Electrically polarised hydroxyapatite is being studied by K. Yamashita, T. Kobayashi, andcolleagues, at the Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University.
In an oral presentation at the Biomaterial Symposium 2000, they reported that they found that apatite
can be electrically polarised and that the stored polarised energy can be measured. They also implanted
the polarised apatite in a dog, to evaluate bone formation, and found that new bone started to form on
the negative surface in less than a week. This phenomenon can find application in orthopaedic and
dental fields. The polarisation can stay in vivo for at least six months.
Surface modification of HAP with carboxyl group was reported by Dr. T. Matsumoto, and
colleagues, of the Dental School, at Osaka University, together with Dr. M. Okazaki, of Hiroshima
University, and Dr. Taira, of the Iwate Medical University. Their idea is based on the fact that bonegrowth factors such as b-FGF and BMP have affinity to negatively-charged surfaces. They succeeded
in producing HAP modified with a carboxyl group and evaluated the material using rats. They found
that the weight of the adhered protein and the cell adhesion ability depend on the volume of the
carboxyl group on the surface.
Zinc-releasing calcium phosphate on collagen is being studied for the promotion of bone generation
by Dr. Atsuo Ito, and colleagues, at the National Institute for Advanced Interdisciplinary Research
(NAIR), together with T. Hikita, and colleagues, at the Waseda University. They made a NaCl,
CaCl22H2O, KCl, ZnCl2 solution, introduced CO2, NaHCO3, Na2HPO412H2O, and put collagen sheet
in it. Low crystal apatite containing Zinc was obtained.
Dr. H. Kawamura, Kennan Hospital, together with Dr. Ito, at NIAIR, and S. Miyakawa, at the Tsukuba
University, conducted a long-term implantation test ofZinc-releasing calcium phosphate ceramics in
rabbits. At an oral presentation at the Biomaterial Symposium 2000, they reported that
0.316%ZnTCP/HAP significantly increased the bone-binding ratio but also increased bone absorption.
They are currently optimising the zinc content.
At a poster presentation at the Biomaterial Symposium 2000, results with magnesium-containing CO3
apatite-collagen composite were reported by Dr. Yasuhiko Yamasaki, of the Dental School of
7/28/2019 Biomaterial Research Japan
16/69
16
Hiroshima University, together with Y. Hamada, and colleagues, of the Dental School, at Osaka
University. They tried to synthesise crystals of magnesium-containing CO3 apatite starting from a
Ca(CH3COO)2H2O and Mg(CH3COO)24H2O solution. The powder crystal obtained is mixed with
0.5w% collagen to produce cylindrical pellets. The pellets are put in serum containing mouseosteoblasts. Adhesion assays revealed that the Mg composite showed higher adhesion than non-Mg
CO3 apatite.
Dr. Tanaka, at the Research in Inorganic Materials, and Prof. Miyairi, at the Tokyo Medical and Dental
University, are collaborating on creating a composite ofpolylactic acid and TCP for bone deficiency
20mm and over. They produced the composite with 20-50% polylactic acid and 80-50% TCP to make
0.3mm membranes. With conventional materials, only a 5mm bone deficiency can be rebuilt.
Carbonate apatite is being studied by Dr. Masahiro Hasegawa, and colleagues, in OrthopedicSurgery, at the Asahi Memorial Hospital, because human bone contains carbonate ions. They reported
at a poster presentation at the Biomaterial Symposium 2000, that they implanted porous apatite with 6
wt% carbonated ions in rabbits. Increased bone forming and the absorption of the material were
observed four weeks later.
Prof. Masanori Oka, Kyoto University, is developing artificial joint cartilage with titanium fibre
mesh injected with PVA hydrogel under high pressure. The properties of lubrication, shock
absorption, and the bio-affinity and adhesion to the bone bed are acceptable, except for the anti-
abrasion. Therefore, the material is suitable for partial hemiarthroplasty for fractures of head of the
thigh bone, osteochondritis dissecans, and chondromalacia. This is joint research with China andclinical applications are expected to be appear in a couple of years.
4-5 Bone generation---tissue engineering5
Professor Kunio Takaoka,inorthopaedic surgery, at the Shinshu University, received competitive
funding, of 21 million Yen a year, from Ministry of Education for his research on basic theory and
operation technique of Bone Morphogenetic Protein (BMP). He used a copolymer of polylactic acid
and polyethyleneglycol for the delivery of BMP, as well as for the scaffold. He succeeded in the
regeneration of the upper arm bone of rabbits in eight weeks. But the mechanical strength and
absorption of the scaffold was unsatisfactory.
Prof. K. Shinomiya,of the Tokyo Medical and Dental University, made a block ofHAP and collagen
composite attached with rhBMP and implanted it in a beagle. Bone generation was observed.
7/28/2019 Biomaterial Research Japan
17/69
17
Prof. Takafumi Yoshikawa, of the Department of Pathology at the Nara Medical University, and
colleagues, in co-operation with T. Uemura, and colleagues, at NAIR, have cultured rat marrow cells
to make bone. Immediate bone generation right after the transplantation of the cultured bone was
observed and osteoblast activity was maintained for a long period. The technology was confirmed withosteoblasts in 29 patients with osteoarthritis and rheumatoid arthritis and injuries.
At a presentation at the Biomaterial Symposium 2000, Dr. Ohgushi, in orthopedic surgery, at the Nara
Medical University, reported that he is going to culture marrow cells of patients who undergo bone
shaving surgery, taking marrow liquid and culturing the cells for three weeks to transplant them to the
patients.
Professor Kinoshita, of the Kanagawa Dental University, has machined PLLA (poly-L-lactic acid) to
meet the shape of the jaw and put sponge marrow taken from waste bone, regenerating jaw bone in six
months to one year. He has performed the procedure, clinically, 50 times. The success rate is 80%.
The National Institute for Research in Inorganic Materials and Institute of Biomaterials and
Bioengineering, Tokyo Medical and Dental Universityhave succeeded in developing a complex of
tricalcium phosphate (TCP) 70% and polylactic acid 30% to make 0.3mm thin membranes to
regenerate lost bone as much as 20mm wide. TCP accelerates bone generation and absorption rate of
the materials can be controlled by changing the ratio of the two materials. Moreover, the membranes
thermoplasticity makes it easy to form various shapes during surgery.
Guoping Chen, and colleagues, of the 3D Tissue Engineering Group, NAIR and T. Sato, at the
Graduate School of Medicine, Tsukuba University, have generated cartilage using biodegradablehybrid sponge. At the Biomaterial Symposium 2000, they reported that they introduced collagen
sponge into the pores of a copolymer sponge of lactic acid and glycolic acid. They successfully
cultured, both in vitro and in mouse, the cartilage cells of the knee joints of cows.
Slow release of BMP with gelatin hydrogel was successfully achieved by Dr. Masaya Yamamoto, at
the Institute of Frontier Sciences, Kyoto University. Release control was accomplished by changing the
water content of the biodegradable hydrogel. The hydrogel was a chemically bridged caustic gelatin
with glutalaldehide.
BMP easily dissipates in the human body even if it is injected. Dr. N. Saito, and colleagues, at the
Shinshu University, are developing an injectable DDS for BMP. They synthesised several blocks of
PLA-PEG copolymers, differing in molecular weight, and injected rhBMP-2 and the copolymers at the
temperature of 60 degree C into the front of a mouse femur and evaluated the bone generation.
It was reported in the Nikkei news that Takeda Chemical Industries Ltd. has developed a new
compound contained in slow release polymer capsules, 30 mm in diameter, that promotes the fusion of
fractured bone by activating a natural protein in the body for a month. Takeda is now moving to a
clinical trial after confirming its effect using mice. The compound, with the development name of
7/28/2019 Biomaterial Research Japan
18/69
18
TAK778, was originally licensed from a Hungarian company and improved by Takeda. It speeds up the
healing process of fractured bone by a third.
4-6 Drug delivery system using ceramics
Professor Makoto Otsuka, from the Kobe Pharmaceutical University, is one the most active researchers
of drug delivery systems using bone cement. He has studied apatite cement, bioactive glass and
complex of bioactive glass, each containing indomethacin. He found that apatite cement suppresses
drug release after a week, while bioactive glass allows drug release, even after three weeks. To
overcome the brittleness of the bioactive glass, he also tried bisphenol-a-glycidyl methacrylate and
triethylene-glycoledimethacrylate, resulting in a decrease in drug release after 100 hours.
During tests, he found drug release speed decreases when the calcium concentration in the liquid or the
blood is high. He is trying to apply his finding to a drug release system for osteoporosis patients usingestradiol. Calcium concentration in blood in osteoporosis rats is lower than normal rats, thus estradiol
release in bioactive glass is increased.6
4-7 Ceramics for cancer treatment
It is preferable to irradiate only locally to cancerous tissue. Y2O3-Al2O3-SiO2 glass was reported to be
suitable for local irradiation in 1987 by G.J. Ehrhardt and D.E.Day. It was achieved, with neutron
radiation of 20-30 mm sphere glass, resulting in conversion of89Y to 90Y, which radiates b rays. Dr.
Kawashita, Kyoto University, has shown that only Y2O3 microspheres with a diameter of 20-30 mm can
be easily obtained by high frequency induction heat plasma. Y2O3 shows excellent chemical durability,
better than Y2O3-Al2O3-SiO2 glass. Animal trials using the spheres are about to begin.
Normal cells can survive up to 48C but cancer cells die at around 43 C. Therefore, it could be
effective to heat up cancer tissue in deep parts of bodies, but methods of local heating are not available.
Dr. Kawashita has developed fine crystals of magnetite, iron, or iron zinc ferrite deposited in CaO-SiO2glass matrix and Li ferrite deposited in SiO2-P2O5 glass matrix. The heat generation of these
ferromagnetic spheres has been tested using rabbits. Other ferromagnetic spheres with higher heat
generating efficiency are under study.
5 Metal7
5-1 Artificial Joints Market
7/28/2019 Biomaterial Research Japan
19/69
19
Market
Units of artificial joints
1998(pieces) Growth rate(%) 1999(pieces) Growth rate(%)
Hip joints 55,742 2.2 58,932 5.7
Knee Joints 27,527 6.9 30,287 10.0
Shoulders 835 0.6 865 3.6
Knees 362 16 470 29.8
Others 508 1.8 705 38.8
Total 84,974 3.7 91,259 7.4
Source: Yano Group
Sales of artificial joints
1998(million Yen)
Growth rate(%)
1999(million Yen)
Growth rate(%)
Hip joints 40,071 2.6 42,488 6.0
Knee Joints 18,028 -0.1 19,951 10.7
Shoulders 418 12.9 418 0.0
Knees 160 25 217 36.6
Others 184 -1.4 260 41.0
Total 84,974 1.9 63,335 7.6
Source: Yano Group
Titanium alloys are increasingly used instead of SUS316 Co-Cr alloys (approximately 80 % of themarket) and have been receiving attention from researchers.
Major manufacturers
Companies Market share
(%)
Notes
Stryker Japan 26
BMS Zimmer 25
Debu Japan 12Kyocera 11 Kyocera has made 8,700 zirconia-based joints
since 1995.
Kobelco 2 The top titanium maker in Japan
K-MAX hip joints
Mizuho Medical
Nemoto Trading
Nakshima Propella
The market share of domestic companies is about 14% including Mizuho Medical, Nemoto Trading,
and Nakashima Propeller, in addition to Kyocera and Kobelco.
7/28/2019 Biomaterial Research Japan
20/69
20
Nakashima Propeller Co. Ltd. is expanding their artificial joints business to USD 20 million in five
years, three times the current amount. They are competitive in titanium alloys rather than ceramics.
Research Direction
Metals for orthopedic applications
(1)Vanadium-free Titanium alloys to replace the most popular Ti alloy: Ti-6Al-4V, that contains
cytotoxic Vanadium.
(2)Alloys with low modulusclose to that of real bone.
(3)Nickel-free shape memory and ultra-elastic alloysNickel may have adverse physiological effects.
Soft bone and cartilage:
Replacement of only a part of cartilage with artificial bone has not been clinically successful, therefore,
joints are completely replaced. Furthermore, the abrasion of joint sliding surfaces is an issue.
(1)Cross-linking of ultra high molecular weight polyethylene
(2)Alumina-alumina sliding surface and composites of zirconia and alumina
Dental applications:
(1)Alloys with low melting point are desired.
(2)Alloys easy to machine are desired
5-2 Titanium alloy on the market
A Vanadium-free alloy, Ti-6Al-7Nb, has been developed and put into practical use in Europe. In Japan,
a few Vanadium-free alloys are on the market or under research.
The Medical Material Division at Kobelco Co. developed Ti-15Mo-5Zr-3Al for cement-type hip
joints and Ti-6Al-2Nb-1Ta for cement-less hip joints. The objectives of Kobelcos development were
to avoid Vanadium and to achieve high fatigue strength. Ti-15Mo-5Zr-3Al was put into clinical trials in
1991 and has been used since 1995. Because its fatigue strength is 20% higher than that of Ti-6Al-4V,
the stem neck out-diameter can be made as small as 9mm.Therefore, the moving area of hip joints is
larger, which results in longer life for the joints.
Ti-6Al-2Nb-1Ta was put into a clinical trial on 1992 and onto the market in 1996. This alloy is less
susceptible to strength deterioration after heat treatment.
7/28/2019 Biomaterial Research Japan
21/69
21
Kobelco so far has used Ti-15Mo-5Zr-3Al with 3,500 patients and Ti-6Al-2Nb-1Ta with 2,000
patients.
5-3 Titanium alloy under research
Yoshimitsu Okazaki, at the Mechanical Engineering Laboratory under MITI, has developed, in co-
operation with Kobelco, Ti-15Zr-4Nb-4Ta-0.2Pd. Zr was added for higher strength; Nb and Ta were
added for improved anti-corrosion; Nb and Ta content was kept low for a lower melting point. The
composition of the alloy was optimised for a good balance of bio-compatibility, improved anti-
corrosion, and a low melting point. The alloy is currently being tested on rats.
Dr. D. Kuroda and Professor Mitsuo Niinomi, at the Toyohashi University of Technology; Dr. Fukui,
and colleagues, of the Dental School, Aichi Gakuin University; T. Kasuga, of the Nagoya Institute of
Technology; and Daido Special Steel Co. are developing Ti-29Nb-13Ta-4.6Zr alloy. The goal is to
design a new b-type titanium alloy that has a similar Young modulus as bone, but without using
cytotoxic materials. Biocompatibility of the alloy, evaluated via cell survival ratio, is the same as
titanium and better than Ti-6Al-4V.
They have also coated the alloy with calcium phosphate glass: 60CaO30P2O53TiO2 to improve bio-
compatibility, and found that the adhesion of the glass to the alloy is extremely strong.
Professor Hideki Hosoda, of Tsukuba University, an expert in shape memory alloys, is developing Ti-
based, Ni-free, shape memory. He has so far achieved good mechanical properties and high modulus
by adding Nb/Mo forb-phase stability and Al/Sn/Ga fora-phase stability. It seems he can develop
shape memory alloys with the specified elements, for medical use. He is looking for commercial
collaboration with researchers in the medical field, to study corrosion and bio-compatibility.
5-4 Metals for dental application
Dr Yoneyama, and colleagues, of the Institute of Biomaterials and Bioengineering, Tokyo Medical and
Dental University, are studying Ti-6Al-7Nb alloy produced by Daido Special Steel Co., for dental
casting application. They concluded that the alloy is promising because it is much easier to machine
than titanium and gives a clear smooth surface. Ti-Ni alloy wire produced by the Furukawa Electric Co.
showed ultra elasticity, which is a good for a material from which to develop a new functional device.
The titanium had an apatite coating
7/28/2019 Biomaterial Research Japan
22/69
22
A Ti alloy that is easy to machine is under study by Dr. Takada, and colleagues, at the Tohoku
University Dental School. They found that the addition of Ag or Cu improves two or three fold the
ability to machine the alloys.
Shu, and colleagues, at the Nagoya Institute of Industrial Technology under MITI, have shown that the
addition of Si, Ca and B in casting machines for dentists improves mechanical properties, for
example, by increasing tensile strength two fold.
Prof. Michio Ohta, at Kyushu University, has found from theoretical calculations that the optimum
composition for age-hardening alloys at mouth temperature is Au 50%, Cu 44% and Ga 6%.
Actually, an alloy with the above composition, plus Ir for finer crystal grains, has been commercialised
under the brand name Sofard.
Surface treatment of titanium using super critical water is under study by Dr. Ban, and colleagues,
at the Aichi Gakuin University Dental School, with the aim of increasing adhesion. The sheer bonding
strength of veneer resins to titanium was increased approximately 25% after super critical water
treatment.
5-5 Surface modifications
The National Industrial Research Institute of Nagoyahas succeeded in coating titanium alloy with
hydroxyapatite. They covered the alloy with titanium metal and then added hydroxyapatite particles
with a 30 mm diameter and heated up to 800-900C under pressure. They are going to proceed with
animal tests.
Professor Kokubo, of Kyoto University, in co-operation with Kobelco Co., is developing the formation
ofamorphous of graded sodium titanate layer on the surface of titanium in order to facilitate apatite
formation. It is a three-year study beginning in 1999 with 200 million Yen funding from the Japan
Science and Technology Foundation under the Science and Technology Agency.
The National Research Institute for Metals has a biometal research group called Center of Cell
Engineering headed by Dr. Hanawa. They focus on basic research on the interaction of cell and
metal:
-Changes in metal surfaces in vivo,
-Cell adhesion to an evaporated film of pure metal,
-Corrosion behaviour of amorphous alloy in a pseudo-bio environment,
-Electrochemical analysis of pure Titanium and SUS316L with culturing cells.
7/28/2019 Biomaterial Research Japan
23/69
23
Dr. Masao Yoshinari, and colleagues, of the Department of Dental Materials Science, Oral Health
Science Center, Tokyo Dental College, is studying surface modifications of titanium to suppress the
attachment of oral bacteria. They found that fluorine implantation on titanium polished surfaces
decreases the proliferation of bacteria.
Dr. Kawabe, and colleagues, of the Okayama University Biomaterial Lab., Faculty of Engineering, are
studying the control of apatite-forming ability on the titanium surface using an electrochemical
technique.
Dr. Shunsuke Fujibayashi, at the Graduate School of Medicine, Kyoto University, is studying the effect
ofsodium removal treatment on the bone bonding ability of bioactive titanium prepared with alkali
and heat treatment.
5-6 Other Metals
(1) Prof. Nakajima, at Osaka University, started the project called Development of advanced
medical equipment using porous metal supported by the government Millennium Project. It is a three
year project, from 20002002, at a total cost of USD 1.5 million. The project involves Yokohama
Medical University, Asahi Intec Co. as well as other science and technical universities. The Lotus-type
porous metal so far developed by the professor has uniform straight pores of 1-10 mm and a pore ratio
of 80%. They are aiming at making the porous metal with stainless steel, titanium, and shape memory
alloy to make guide wires, stents, artificial bone, and dental implants. According to Business &
Technology News, the market for guide wire and stents is USD 360 million with an annual growth rateof 23%, and the number of cardiovascular patients is 3.3 million. The market for artificial bone, joints,
and dental implants is USD 200 million with 14% annual growth with 3.2 million osteoporosis and
arthritis patients.
(2) Prof. Shinichi Nittas group, from Tohoku University, and Tokin Co. have jointly developed
artificial cardiac muscle with shape memory alloy to be attached on the outside of hearts. The
muscle is a Peltier effect element sandwiched by shape memory alloy plates. The size is 1cm*5cm with
0.5 cm of the thickness due to the Ni-Ti alloy. The power is supplied from outside the body by
electromagnetic induction. The group tested the effect using a goat.
6 Polymers and Lipids8
There were 40 presentations in the July 2000 Medical Polymer Symposiums. Many researchers are
working in this field for various applications such as drug delivery systems, gene delivery systems, and
scaffolds. Targeting and gene delivery is one of the most exciting challenges.
7/28/2019 Biomaterial Research Japan
24/69
24
6-1 MS Coat
MS Coat is the brand name of a desensitiser sold by the SUN MEDICAL CO. to relieve patients with
hypersensitive teeth. It was developed by the SUN MEDICAL, a subsidiary of Mitsui Chemical Co.,
and has been on the US market (Parkell Co. is the sales representative) since 1996 as Pain-free
desensitiser. It began sales in Japan in October 1999, through the Morita Co.
Its main component is a copolymer of methyl methacrylate and styrenesulfonic acid originally
developed by Prof. Nakabayashi, Institute of Biomaterials and Bioengineering Tokyo Medical and
Dental University.
A clinical trial done by the Tohoku University and the Tokyo Medical and Dental University showed
that 87% of patients with hypersensitive teeth achieved immediate relief after just one coating and 82%
remained pain-free even after one month. It consists of liquid-A: a MS Coat and liquid-B: calciumcompound.
6-2 MPC 9
A 2-metacryloyloxyethyl phosphorylcholine (MPC) polymer contains a phospholipid polar group
(phosphorylcholine group), the structural component of biomembrane; and a metacryloyl group, which
has polymerisation capability with many monomers. MPC polymer reacts extremely weakly with
biocomponents such as proteins and blood cells and shows a quite excellent thrombus resistance. Many
researchers, both domestic and abroad, are working on using MPC with blood cleaners, implant
sensors, blood pumps, blood circuits, artificial blood tubes, and drug carrier nanospheres.
MPC polymer was originally synthesised by Professor Nobuo Nakabayashi, at the Tokyo Medical and
Dental University, in 1978. Professor Kazuhiko Ishihara of the Department of Materials Engineering,
Faculty of Engineering, at the University of Tokyo has established volume production technology of
MPC funded by the government.
NOF Corporation (Nippon Yushi Co.) has completed a commercial plant for MPC, from monomer
through polymer, and anticipates various applications such as contact lens cleaning liquid, catheters,
and intraocular lens.
The combination of MPC with other materials such as polysulfone membranes and segmented
polyurethanes is one of the research themes of the above groups.
6-3 Photoreactive polymers
Dr. Yasuhide Nakayama, an expert in photoreactive polymers, at the National Cardiovascular Disease
Center Research Institute, has synthesised, in co-operation with Prof. Takehisa Matsuda, of Kyushu
University, photoreactive gelatin by introducing side chains to the benzophenon group, which generates
7/28/2019 Biomaterial Research Japan
25/69
7/28/2019 Biomaterial Research Japan
26/69
26
6-5 Polymeric Micelles
Professor Kataoka, at Tokyo University, studies polymeric micelles and intelligent biomaterials. Block
copolymers that have both hydrophilic and hydrophobic polymer chains in a molecule form micelles, inwater, with hydrophilic chains outside and hydrophobic chains inside. The micelles are excellent drug
carriers, because they can hold drugs firmly in their inner cores and control the drug release by
changing the molecular structure of the inner cores. Since polyethyleneglycol (PEG) is used for the
hydrophilic chains, the immune system does not recognise the micelles as foreign materials. The
micelles also have an enhanced permeability and retention effect, useful for tumour targeting. Micelles
containing doxorubicin have been shown to be highly effective against tumours.13
Dr. Kataoka is also developing a glucose-responsive insulin release system using the equilibrium of
phenylboronic acid in aqueous solution. He has made a gel by introducing acrylamidephenylboronic
acid (AAPBA) to N-isopropylacrylamide (NIPAAm). The gel can release or retain insulin (on and off)
in accordance with the glucose concentration.14
He and Prof. T. Aida, from Tokyo University, are applying micelles to DDS for cancer, with a
porphyrin dye covered by dendrimer. Porphyrin purges active oxygen in response to light radiation and
attacks cancerous cells. The dendrimer is positively-charged, therefore, it tends to attach to the surface
of cancerous cells. Thus, the micelles have 28 times more capability of killing cancerous cells than
porphyrin alone. Kataoka is planning to cover the micelles with lipid particles, with the diameter of 50
nm, because he already showed that lipid particles gather efficiently around cancerous cells.
6-6 Nanoparticles and Microcapsules
(1) Mucosal peptide delivery systems are under development by Prof. Kawashima, and colleagues,
at the Gifu Pharmaceutical University. They have succeeded in developing lactide glycolide copolymer
(PLGA) nanospheres containing peptides. They have also succeeded in modifying the surface of the
nanosphere with chitosan, for mucosal adhesion. This is because mucosa has a negative charge and
chitosan is positively charged, thus the movement in the digestive tract is delayed. They have shown
the prolonged effect of calcitonin using rats.
They have also made powdered nanospheres for pulmonary delivery that coagulate when inhaled and
disperse in the lung and thus function as nanospheres. They have observed that the dextranconcentration in blood is extended by using the powdered nanospheres.
(2) Prof. Kikuchi, and colleagues, of the Nara Institute of Science and Technology, have succeeded
in developing unique spheres with silicon oxide on the surface of a liposome. The diameter of the
sphere is 200 nm. The silicon oxide layer is 5 nm. They named the spheres, Cerasome. There were
problems with adhesion or deformed shapes due to the soft surface of the liposomes. The siliconised
spheres will solve such shortcomings. The researchers are going to add bio-affinity to the surface.
(3) Prof. Takayama, and colleagues, of the Hoshi Pharmaceutical University, have developed a
neural network system to get the optimum mixing ratio of various materials in order to achieve a micro
7/28/2019 Biomaterial Research Japan
27/69
27
capsule of a certain diameter. For example, by mixing three materials, such as a component in
soybeans, cholesterol and oleic acid, to form a capsule suitable for drug delivery to a cancerous part of
the liver, 15 experiments will be enough to get a regression formula in order to determine the ratio for
the mixture. At present, as many as 1,000 experiments are needed to determine the optimum ratio.
(4) Dr. Ichijou, and colleagues, of the National Institute of Materials and Chemical Research, are
working on molecularly imprinted polymers. They have succeeded in synthesising polymer
microspheres that can discriminate for oxytocin.
6-7 Liposomes
Prof. Konno's group, at the Research Institute of Advanced Science and Technology, Osaka Prefecture
University, are studying functional liposomes modified with polymers. They have succeeded increating a temperature-sensitive liposome that releases drugs at a temperature slightly higher than body
temperature. The temperature response of the liposome copolymer depends on a kind of lipid, for
example, egg yellow phosphatidylcholine did not show remarkable drug release in temperatures higher
than the lower critical solution temperature (LCST). But adding dioleoilphosphatizylethanolamine
(DOPE) gave a very sharp temperature responsive liposome. They have synthesised copolymers, such
as NIPAM-AAM (poly-N isopropylacrylamide-Acrylamide) and NIPAM-N-APr (Acryloylpyrolidine),
that have LCST around 40 degrees C.
A cationic liposome modified with N-APr has also been synthesised. The affinity with negatively
charged membranes is controlled by heating.
They have also synthesised succinylated polyglycidol, which showed high membrane fusion ability. It
can be used for a delivery system into cells.
6-8 Polysilamine
Associate Professor Sachio Nagasaki, at the Science University of Tokyo, is studying polysilamine, anew heterotelechelic oligomer. It can be prepared through an anionic polyaddition reaction between
divinyldimethylsilane and 3,6-diazaoctane. It is a gel, with more flexibility than natural gum, but swells
and turns solid with a pH change from alkali to acid. Applications for artificial muscle, drug delivery
systems, and sensors are anticipated.
7/28/2019 Biomaterial Research Japan
28/69
28
6-9 Perfluorocarbonic acid
Dr. Azumi, and colleagues, of the Osaka National Research Institute, are studying the displacement
characteristics of gold plating on perfluorocarbonic acid membranes, which has been developed byAsahi Glass Corporation. The displacement occurs in response to an electric field. The degree of the
displacement depends on the type of counter ions. They have applied the technology to micro catheters
that bend in an electric field.
6-10 Shape Memory Gels
Dr. Takashi Miyazaki, and colleagues, of the Hokkaido University, are working with shape memory
polymer gels prepared from acrylic acid and stearyl acrylate. The shape memory effect takes place at
the transition between the amorphous state in the dry condition and the crystalline state, formed withthe addition of a certain amount of water. Their aim is to create a reliable valve.
6-11 Hollow fibres
Hollow fibres are used for dialysers, and artificial lungs.
Materials and the manufacturers of hollow fibres
Makers AsahiMedical Kuraray Nikkiso Teijin Terumo Toray Toyobo
Regenerate
Cellulose
* *
Cellulose
Acetate
* *
Polyacryl-
nitril
*
Polymethyl-
methacrylate
*
Ethylene
vinylalcohol
*
Polysulfone * * *
Polyester-
polymer alloy
*
Synthetic polymers are now more used in place of cellulose, with polysulfone as the most popular.
7/28/2019 Biomaterial Research Japan
29/69
29
7 Drug Delivery and Targeting
At the Controlled Release Society in Paris in 2000, Prof. Okano, from the Tokyo Women's Medical
University, was given the Founders Award for his research on temperature responsive polymers. Dr.
Okada, from the Takeda Pharmaceutical Co., and Dr. Toda, a former Takeda employee, now with
Ohtsuka Pharmaceutical Co., were also honoured with the Nagai Innovation Award for their invention
ofLeuprin and its success on the market. It is proof that Japan is world-class in both research and
commercialisation of DDS.
7/28/2019 Biomaterial Research Japan
30/69
7-1 Overall situation
Current status of fine particles used in DDSKinds Materials Size Characteristics Sustained
drugs
Exa
rese
Liposomes Lecithin, Cholesterol,
Charged substances
20nma
few mm
Suitable for localising,
targeting, slow release,
surface modification,
and activation of
microphage
water-soluble
& lipid-
soluble
Top
Mo
anti
Hem
Cat
Con
con
Lipid
microspheres andnanospheres
Lecithin, Soya oil,
Olive oil
0.2 mm
(ave.)
Lymph targeting,
Thermal sterilisation
lipid-soluble new
lipoamp
(50
Emulsion Synthetic surfactants,
Oily substances
Greater
than 0.1
mm
Used mainly for
embolisation and
absorption
enhancement
water-soluble
& lipid-
soluble
Art
cell
Ora
insu
PTH
Mixed micelles Synthetic surfactants,
Unsaturated fatty
acids
5 nm Enhancing absorption
in intestines
lipid-soluble
Polymer micelles Synthetic polymers 50200
nm
water-soluble
& lipid-
soluble
Adr
Cal
PA
cop
7/28/2019 Biomaterial Research Japan
31/69
7/28/2019 Biomaterial Research Japan
32/69
32
7-2 Active targeting15
Prof. Kitajima, at the Medical School, Keio University, in co-operation with Associate Prof. Imoo, at
Okayama University, made ribonuclease combined with EGF by joining the genes ribonuclease and
EGF and introducing them into E. coli. Ribonuclease is an enzyme that destroys RNA and inhibits
protein synthesis, thus killing cancerous cells. Cancer cells have receptors that bind EGF, a cell growth
factor. The combination was effective in a mouse transplanted with cancer cells.
In addition to EGF, the transferrin receptors and galactose receptors of the liver cancer cells are under
study by Prof. Hashida, at Kyoto University and Prof. Kataoka, at Tokyo University.
Dr. Kataoka is also trying to bond recognition molecules to micelles, to provide both passive and active
functions.
7-3 Passive Targeting16
The EPR effect (enhanced permeability and retention effect) was discovered by Dr. H. Maeda. Through
this effect, polymers are selectively accumulated in cancer tissues compared with normal tissues.
SMANCS is a DDS drug utilising this effect.
Liposomes modified with polyethyleneglycol can reduce non-specific interactions and suppress uptake
into the reticuloendothelial system. Prof. Maruyama, at the Faculty of Pharmaceutical Science, Tokyo
University, reported a remarkable increase in residence time in the blood with the modified liposomes.
Polymer micelles that have been developed by Prof. Kataoka are now being tested in a DNA delivery
application.
7-4 Stimulus Responsive Materials
The following are not necessarily focusing on DDS but on intelligent materials.
(1) Prof. S. Aoshima, at Osaka University, is studying living cation polymerisation of vinylethers under
an additive base. For example, polyvinylether, with oxyethylene on side chains, is water-soluble at low
temperatures but shows phase-separation at a certain temperature (Tps). Tps is changeable by the kind
of side chains or random copolymerisation. When the polymer is mixed with polycarbonic acid, it
separated at below a certain pH (CpH) to form a complex.
(2) The New Energy and Industrial Technology Development Organisation (NEDO) started a five-year
research programme called Advanced Stimuli-Responsive Materials in 1996. The programme is
focused the intellectual environment responsive functions of biological systems used as industrial
7/28/2019 Biomaterial Research Japan
33/69
33
materials. The programme has the three targets: 1. Separation materials, 2. Control release materials, 3.
Actuating materials.
Research on control release materials is conducted at the Osaka National Research Institute in co-operation with Prof. Nagata, of Hokkaido University; Prof. Okano, of the Tokyo Womens Medical
University; Prof. Kataoka, of Tokyo University; Prof. Akashi, of Kagoshima University; Prof.
Kajiwara, of Kyoto Institute of Technology; and some companies.
Under the programme, Dr. Ueno, of the National Institute of Materials and Chemical Research, in co-
operation with Tokyo University and Chisso Corporation, is studying magnetic nano particles attached
with ligands or nucleonic acid. The particles can be easily recovered using magnets. They
copolymerised acryloylglycineamide and biotin monomer, and, just by mixing the copolymer with the
magnetic particles, they can get temperature responsive magnetic nano particles that aggregate at less
than 20 degrees C and disperse at a higher temperature. This technology has the potential to produce
molecular recognition and temperature responsive magnetic particles.
7-5 Electromagnetic Responsive Double Targeting17
Professor Takeshi Kobayashi, in Bioengineering at Nagoya University, is developing Electromagnetic
Responsive Double Targeting, in a combination of time targeting, controlled release by physical
stimulations from the outside, and space targeting, collecting medicines to a target area by use of
monoclonal antibodies and others.
Dr. Kobayashi is a developer of magnetic nano-spheres, which heat up in response to an alternating
magnetic field. He uses carboxy-methyl cellulose (CMC) and 25nm magnetite in a 4/1 weight ratio to
form extrusion needle-shaped magnetite 2-3 mm in diameter.
Dr. Wakabayashi of Nagoya University Medical School, has found a use for magnetic nano-spheres in
treatment of brain tumours. Liposomes containing magnetic nano-spheres were injected into rat
tumours and a 120Hz magnetic field was applied. The tumour disappeared through the heat generated
by the particles and the magnetic field. This was also successfully used in rabbits. A monoclonal
antibody that binds to tumours has been developed for brain tumours.
Magnetic nano-spheres are used for extracting target substances in blood. An antibody for insulin, for
example, is attached to the particles, then put into blood. Insulin bind to the particles. Insulin is thus
measured at a higher concentration. Glycosylated hemoglobin and fructosamine can also be measured.
This way diabetes can be diagnosed in 30-40 minutes with 50 ml of blood. The method is now being
marketed by a venture company called M-Bio.
7-6 Biomolecular Design for Biotargeting
7/28/2019 Biomaterial Research Japan
34/69
34
Biomolecular Design for Biotargeting was accepted by the Ministry of Education and Science from
1998 to 2000 as one of the Grant-in Aid Programmes for the Scientific Research on Priority Areas. The
goal of the programme is to review the targeting function of living cells or biomolecules and to
reconstruct it from chemical and engineering points of view. The programme consists of the followingfour research fields involving more than 70 researchers in universities:
1) Biomolecular recognition, represented by Professor Imanaka, Kyoto University
-Modifications of the molecular recognition capability of antibodies
-Signal transmitting function of antibodies
-Modifications of enzymes for molecule recognition analysis
2) Biomolecular architecture, represented by Professor Matusnaga, Tokyo Agriculture and
Engineering University
-Building a biomolecule architecture on the surface of magnetic nano-spheres and liposomessynthesis of a biomolecular architecture
Electromagnetic Responsive Double Targeting, described in the previous chapter, is one of the
outcomes of the programme.
3) Cell surface design, represented by Professor Tanaka, Kyoto University
-Culturing new functional micro organism cells
-Producing biovaccines with antigen presenting cells
Modifications of cell function by expressing chimera receptor molecules on the surface of animal
cells
Analysis of cell surface functions using artificial cells
4) Biotargeting, by Professor Kobayashi, Nagoya University
-Tissue and cell targeting of functional materials incorporated with biopolymers
Targeting of physiologically functional small molecules with stimulus-responsive polymers
Biomolecule targeting with an ultra-micro electrode device
7-7 Transdermal & Transmucosal Delivery
The Suguhara group has conducted a study of how drugs applied on the skin remain locally in dermis
or hypodermis or move to the entire body through blood vessels.18 The movement of a drug in skin is
rather complicated; therefore, the development of simple evaluation is indispensable.19
The direct transport of a drug from the nasal cavity to the cerebrospinal fluid was reported recently;
therefore, targeting the brain is possible.20
7/28/2019 Biomaterial Research Japan
35/69
35
How to obtain slow release of a drug and adhesion to mucosa is important, but on-off control of drug
release is also of interest. Polymer gels that change structure in response to temperature, pH, electric
fields, light, ultrasonic, and chemical substances are being studied by Prof. Okana's group.21
Studies on how to enhance the absorption of a drug in skin or mucosa have been carried out by the
Josai University group.22 Two Kyoto groups have studied absorption enhancing reagents.23
Electroporation is a relatively new method to enhance absorption.24 The Sugihara group reported that
pretreatment of a non-needle syringe increased the transdermal absorption of a drug.25 Phonophoresis
has also been used to enhance absorption.26
7-8 Company activities
(1) Leuprin, launched by the Takeda Pharmaceutical Co., is the most successful polymer nano-sphereDDS. It is sold in more than 10 countries, including the USA, with the annual sales of more than USD
1 billion. In 1989, Drs. Ogawa, Okada, Toda, and colleagues, at Takeda, succeeded in putting
leuprolerin acetate, an antagonist of the luteinising hormone-releasing hormone, in microspheres. The
microshperes, made of a copolymer of polylactic acid and glycol acid, to keep released leuprolerin for
more than a month after a one-time injection. It is currently used for the treatment of prostate cancer
and breast cancer.
(2) SMANCS, developed by Prof. Maeda, at the Medical School, Kumamoto University, and launched
by the Yamanouchi Pharmaceutical Co. in 1996, is the first and only polymer anticancer drug approved
by the Ministry of Health and Welfare. It is a styrene-maleic acid conjugate of neocarcinostatin. The
molecular weight of SMANCS itself is 16,000, but it bonds with albumin in the human body to behavelike a polymer with 80,000 MW. It gathers and accumulates around cancerous tissue, a phenomena
Prof. Maeda discovered in 1986 and called theEPR effect. SMANCS can be oil-philic by the butyl-
esterification of the carboxyl group of the styrene-maleic acid copolymer, thus, increasing the affinity
to lipiodol. Therefore, both the targeting and controlled release of lipiodol are achieved.
(3) A venture company called NanoCarrier Co., located in Chiba prefecture, has developed micelle-
type DDS that accumulate drugs near tumour tissues. The materials are molecules of hydrophilic
polyethyleneglycol (PEG) bonded with hydrophobic polyaminoacid. The particles have a diameter of
20200 nm. In an experiment using mice, the anticancer drug contained in the micelle accumulated
near the tumour tissue at a concentration seven times higher than the drug alone. They explain that
micelles normally cannot pass through blood vessels around healthy cells, but that passages in blood
vessels around cancerous cells are large enough for the micelles to go through.
(4) The DDS annual conference was held in July 2000 in Akita, Japan. The following information
related to biomaterial DDS was reported at the proceedings.
Nippon Shinyaku Co. is developing new drugs using lipid ultra fine particles (LNSTM) that contain
soybean oil and egg yellow lecithin and have a diameter of several dozen nano-metres. LNS does not
go to the liver or the spleen and has passive targeting capability.
7/28/2019 Biomaterial Research Japan
36/69
36
Welfide Co. is developing bromperidole, a drug for mental illness, contained in slow release polylactic
acid microspheres.
NOF Corporation (Nippon Yushi Co.) is ready to sell highly pure liposome for medical applications.
Ohtsuka Pharmaceutical Co. is studying liposome triggering cytokine production in human peripheral
blood cells.
8 Gene Delivery
8-1 Gene Therapy Protocols
Protocols for gene therapy that have been approved by the Advanced Medical TechnologyEvaluation Committee in the Ministry of Health and Welfare by the end of 2000.
No Date of
approval
Diseases Vectors/Gene Hospitals Number of
patients treated
1 1995 Feb. ADA
deficiency
Retro virus Hokkaido Univ. 1 (1995)
2 1997 May HIV infection Retro virus Kumamoto
Univ.
3 1998 Aug. Kidney cancer Retro virus Tokyo Univ.
Medical Institute
3
4 1998 Oct. Lung cancer Adenovirus Okayama Univ. 8
5 2000 May Esophagus
cancer
Adenovirus/
P53
Chiba Univ. 1
(19/12/2000)
6 2000 Feb. Breast cancer Retrovirus Japan
Foundation for
Cancer Research
7 With-drawn Liver cancer Adenovirus Tokyo Univ.
Medical Institute
8 2000 Jan. Malignant
gliomaCationic
Liposome
Nagoya Univ. 1
9 2000 Jan. Lung cancer Adenovirus Tokyo Jikei
Medical Univ.
1
10 2000 Jan. Lung cancer Adenovirus Tohoku Univ. 1
11 2000 Jun. Prostate cancer Adenovirus Okayama Univ.
12 2000 Jan Lung cancer Adenovirus Tokyo Univ.
Medical Institute
13 Under examin-
ation
Chronic
obstructive
arteriosclerosis
DNA alone Osaka Univ.
7/28/2019 Biomaterial Research Japan
37/69
37
As seen in the above table, Nagoya University is the only group that used non-virus vectors for clinicalstudies of gene therapy. Dr. Yoshida, and colleagues, have been developing gene therapy for malignant
glioma with the IFNb gene, using a cationic liposome as the vector. Liposomes are synthetic lipid
vesicles that can entrap drugs or genes within their aqueous compartment or lipid bilayer. Dr. Yoshida's
group conducted the first therapy in April 2000. They have also worked on entrapping recombinant
adenoviral vector in multi-layer liposomes to improve transduction efficiency and reduce virus
antigenicity. They have also succeeded, in co-operation with Aichi Medical University, in producing a
single chain antibody for type III mutant EGFR, which expressed in malignant glioma and not in
normal cells.
8-2 Research on non-virus vectors
Cationic liposomes and polycations are the two major materials used for gene vectors.
Prof. Akaike's group in the Department of Biomolecular Engineering in Tokyo Institute of Technology
and Prof. Hashida, in the Pharmaceutical Department in Kyoto University, are some of the major
research groups in the field.
Dr. Prof. Akaike's group, including Dr. Maruyama and Dr. Ishihara, has synthesised a graft
copolymer (comb type copolymer) with poly(L-lysine) as the backbone and hyaluronic acid side
chains. This polymer formed a complex with plasmid DNA. They showed with in-vivo experimentsthat the complex is specifically taken into the liver. They also made graft copolymer of poly(L-lysine)
and arabinogalactan, a kind of polysaccharide, and showed a similar targeting effect to the liver. They
are also studying the expression of graft copolymers in cells. Prof. Akaike is one of the leading
researchers of hybrid livers.
(1) Prof. Hashida, of Kyoto University, and Dr. Kawakami at Nagasaki University, have
synthesised a sugar-modified cationic liposome that created a complex with plasmid DNA. They used a
cholesterol derivative modified with galactose or mannose, both showing high gene expression in the
liver.
(2) Prof. Ogihara, Osaka University Hospital, has applied for permission to provide gene therapy
using catheters, in-stead of vectors, to bring hepatocyte growth factors to the target part of the inner
wall of the heart. Another group in Osaka University has already applied for permission to inject HGF
in cardiac muscle.
8-3 Polycations and Liposomes
(1) Prof. Mayumi and Prof. Nakagawa, of the Department of Pharmeutical Science at Osaka
7/28/2019 Biomaterial Research Japan
38/69
38
University, are studying membrane fusion liposomes, a kind of hybrid vector, with the membrane
fusion capability of a virus. They have also worked on the expression system in cytoplasm.
(2) Prof. Konno's group in Osaka Prefecture University, made a complex of succynilated polyglycidolbonded with transferrin and cationic liposome-plasmid conjugate. It was tested as a gene delivery
system for tumour cells and proved to have high expression efficiency, because plasmid DNA was
introduced into target cells through transferrin receptors.
(3) Increasing the gene-introducing efficiency of cationic liposomes to the level of viral vectors is
being studied by various research groups at the Tokyo University, Tokushima University, and Shizuoka
Prefecture University.
(4) Aomori Prefecture Green Bio Center has applied for permission to use a new gene vector,
positively charged polyornithine fused with plasmid, developed by Agriculture Research Center, to
create herbicide-resistant rice.
8-4 Polymer Micelles
Prof. Kataoka and his group are also applying micelles to non-viral vectors. Polyethylene glycol-poly
a, b-aspartic acid as anion block copolymer mixed with polyethylene glycol-poly L-lysine (PEG-PLL)
as cation block copolymer generates PIC with a diameter of dozens of nano-metres in a sharp diameter
distribution.
Micelles 80 nm in diameter were formed with plasmid DNA and PEG-PLL. Higher expression of
luciferase in cultured cells was obtained with the micelles, compared with conventional lipofectin. He
has also reported an environment-responsive micelle vector by reversible cross linking of the core
through disulfide bonds.
8-5 Fullerene and Cyclodextrin
(1) Prof. Nakamura, of the Science Faculty and Prof. Okayama, of the Medical Faculty in TokyoUniversity have been successful in applying for permission to use fullerene (C60) as a gene vector.
C60 is a cubic molecule with a 1 nano-metre diameter. Profs. Nakamura and Okayama bound DNA,
containing the luciferase gene on an expression plasmid, to positively charged C60, and added them to
a culture of monkeys kidney cells. Expression was achieved in 25% of the cells. Nakamura and
Okayama claim that C60 gradually enters into the nucleus. Thus, C60 can be a DDS. Together with a
pharmaceutical company, they have applied for a patent.
7/28/2019 Biomaterial Research Japan
39/69
39
(2) Prof. Kamigama, Pharmaceutical Faculty, Kumamoto University, is trying to use a conjugate of
cyclodextrin and dendrimer as a gene vector. The conjugate showed higher activity than conventional
LipofectinTM.
9 Tissue Engineering
Tissue engineering has been strongly supported by the government in the past several years and was
chosen as one of the focus fields of the Millennium Project supported by the Prime Minister. A national
centre of tissue engineering, from basic research to clinical development, is being built in Kobe.
Among the significant number of researchers in the field, Kyoto University is a pioneer in this field and
its research is considered world-class. Tissue engineering research in Japan is not lagging behind theUSA, but commercialisation or business applications are clearly behind. Only recently have some
venture companies been created.
According to J-TEC, a venture company for skin culture, the Japanese market potential for tissue
engineering will be USD 8 billion and the world market, USD 45 billion .
Three government-supported research programmes in the tissue engineering field are of note:
The Regenerative Medical Engineering Programme, supported by the Ministry of Education and
conducted by hundreds of university researchers---1996--2000 Hiroshima prefecture Tissue Engineering Project, organised by Professor Katsuoshi Yoshizato, of
Hiroshima University
3D Tissue Module Engineering, conducted by NAIR(National Institute for AdvancedInterdisciplinary Research), under the Ministry of Economics, Trade and Industry (A part of the
Millennium Project supported by the Prime Minister)
9-1 Regenerative Medical Engineering Programme by the Ministry of Education
The programme started in 1996 as a five-year programme with about USD 1 million annually. Theprogramme consists seven groups:
Tissue Engineering for Hard Tissues; Tissue Engineering for Soft Tissues; Biomaterials for Tissue
Engineering; Bioprocess Engineering of Functional Regeneration of Culture; Tissue Engineering for
Organ Regeneration, started in 1996; and, Function Regeneration, and Bio Tissue Engineering, started
in 1997 and 1998, respectively.
7/28/2019 Biomaterial Research Japan
40/69
7/28/2019 Biomaterial Research Japan
41/69
41
readily adhere to them. Therefore, we transferred harvested cell sheets onto another cell type
monolayer and co-cultured them. The other method is a patterned co-culture utilising patterned graft of
PIPAAm by masked electron beam irradiation. One cell type is then cultured to confluency at 37'C.
Reducing the temperature to below 32 'C., the cells are only detached from these grafted patterns.Another cell type is then seeded over the same surface at 37'C. These subsequently seeded cells only
adhere to the now-exposed polymer-grafted domains. Initially, seeded cells remaining adherent on non-
patterned surfaces and cells added in the second seeding are then co-cultured at 37'C together in well-
ordered patterns. These two methods enabled long-term co-culture of primary hepatocytes with other
cell types. Hepatocytes co-cultured with endothelial cells maintained the differentiated functions such
as albumin synthesis for more than two months. These findings might be related to the morphological
resemblance to liver tubule structure in terms of the adjacent lining of hepatocytes and endothelial
cells.
(3)Bioprocess engineering of functional regeneration of culture
Prof. Ohshima, at Tsukuba University Medical School, is the project leader and the objective is to
develop an artificial liver.
They have developed the volume culture of liver cells: a packed-bed reactor using polyvinylformal as a
scaffold. Based on various other studies, they are currently trying to scale up reactors, create model
animals, and a mixed culture of foe